SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride (0.9%) provides isotonic sodium and chloride ions, expanding extracellular fluid volume via osmotic retention of water. Potassium chloride (0.15%) supplies potassium ions necessary for transmembrane electrochemical gradients, maintenance of cellular membrane potential, and neuromuscular function. Combination corrects hypovolemia and hypokalemia.
| Metabolism | Not metabolized; sodium and chloride are excreted primarily unchanged by the kidneys (glomerular filtration and tubular reabsorption); potassium is actively secreted and reabsorbed in distal tubules and collecting ducts. |
| Excretion | Sodium and chloride are primarily excreted renally: >90% of filtered sodium and chloride are reabsorbed in the kidneys; excess is excreted in urine. Potassium is mainly excreted renally (approximately 90%), with minor fecal (10%) and negligible biliary elimination. |
| Half-life | Not applicable as a pharmacokinetic parameter for electrolyte solutions; the elimination half-life of infused sodium, chloride, and potassium is approximately 2-4 hours, reflecting renal clearance and distribution kinetics. In clinical context, steady-state electrolyte concentrations are achieved within 1-2 hours of continuous infusion. |
| Protein binding | Sodium, chloride, and potassium are not significantly bound to plasma proteins; protein binding is <1%. |
| Volume of Distribution | Sodium and chloride distribute primarily in extracellular fluid: Vd approximately 0.2-0.3 L/kg. Potassium distributes mainly in intracellular fluid: Vd approximately 0.6-0.7 L/kg, but initial volume of distribution for infused potassium is smaller (0.2-0.3 L/kg) before cellular uptake. |
| Bioavailability | Intravenous administration: 100% bioavailability. Not administered orally or by other routes; oral bioavailability is not clinically relevant for this formulation. |
| Onset of Action | Intravenous infusion: correction of electrolyte deficits begins within minutes; hemodynamic effects (plasma volume expansion) occur immediately with infusion. |
| Duration of Action | Intravenous infusion: effects persist as long as infusion continues; after cessation, electrolyte levels return to baseline over several hours (2-6 hours depending on renal function). Rapid distribution and excretion result in short-lived effects upon discontinuation. |
Intravenous infusion: 500-1000 mL as needed to correct fluid and electrolyte deficits; rate adjusted based on patient's clinical status, typically 1-2 L/day for maintenance. Maximum rate: 20 mEq/h potassium.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment. GFR 10-50 mL/min: reduce potassium content or use with caution, monitor serum potassium; maximum potassium infusion rate 10 mEq/h. GFR <10 mL/min: avoid potassium-containing solutions unless documented hypokalemia; monitor ECG and potassium levels closely. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium levels; reduce rate if hyperkalemia risk. Child-Pugh C: avoid potassium-containing solutions unless essential; monitor potassium and acid-base status. |
| Pediatric use | Neonates and infants: 0.5-1 mEq/kg potassium per day; titrate based on serum levels. Children: 1-2 mEq/kg potassium per day; maximum infusion rate 0.5 mEq/kg/h. Adjust volume based on daily fluid requirements (e.g., 100 mL/kg for first 10 kg, 50 mL/kg for next 10 kg, 20 mL/kg for remaining). |
| Geriatric use | Initiate at lower infusion rates (e.g., 0.5-1 mL/min for potassium) due to decreased renal function; monitor serum electrolytes and renal function frequently; avoid volume overload (use lower volumes if heart failure or hypertension). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Both sodium and potassium are secreted into breast milk at low concentrations. No M/P ratio is clinically relevant. Use is considered compatible with breastfeeding. |
| Teratogenic Risk | Sodium chloride and potassium chloride are normal physiological constituents. No teratogenic risk is expected at therapeutic doses. Hypokalemia or hyperkalemia may affect fetal development indirectly. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Hypernatremia","Severe renal impairment with oliguria or anuria","Hypersensitivity to any component","Patients with potassium sensitivity or conditions predisposing to hyperkalemia (e.g., untreated Addison's disease, extensive tissue trauma)"]
| Precautions | ["Risk of hyperkalemia or cardiac arrhythmias if potassium is administered too rapidly or in patients with impaired renal function; infusion rate should not exceed 10 mEq/h under most circumstances","Risk of hypernatremia or fluid overload in patients with cardiac failure, renal impairment, or conditions with sodium retention","Monitor serum electrolytes, fluid balance, and renal function during therapy","Use with caution in patients with oliguria, anuria, or severe renal impairment","Do not administer unless solution is clear, colorless, and container is undamaged"] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (Na, K, Cl), renal function, and fluid balance. Assess for signs of electrolyte imbalances such as arrhythmias, edema, or neurological changes. |
| Fertility Effects | No known effects on fertility at therapeutic doses. Severe electrolyte disturbances may impact reproductive function, but these are not drug-specific. |